Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT03051516 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT03051516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 4
Overall status
Terminated
Start date
August 1, 2017
Completion date
December 31, 2022
Enrollment
188 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high grade anal canal intraepithelial neoplasia, high grade vulvar squamous intraepithelial lesion